CStone Pharmaceuticals Co., Ltd (CStone), a
biopharmaceutical company focused on development of next-generation innovative
drugs, has been invited to present an abstract describing research into the molecular
and immunological mechanisms affecting immune checkpoint inhibitor therapy at
the 2018 American Association for Cancer Research (AACR) Annual Meeting, to be held
in Chicago, Illinois, the United States, April 14-18.
The AACR's Annual Meeting brings together
oncologists, scientists, medical professionals, and patients to present current
practices and techniques in the field of cancer prevention and treatment. CStone’s
Director of Translational Science Dr. Ying Pan will present Integrative Genome-Scale Analysis of TCGA
Dataset for Features of Tumor Immunity during the meeting’s morning Poster
Session on April 16.
CStone, supported by Contract Research
Organization (CRO) Crown Biosciences, carried out an
integrative genome-scale analysis across a dataset of 9,338 tumors from 24
different cancers. The aim was to explore variations in inflammatory status within the tumor microenvironment (TME) and correlations
with immune response. In total nine representative
biomarkers were assessed according to T-cell inflamed and non-inflamed tumor
subtypes, with the aim of identifying prognostic significance and potential
impact on administration of immune checkpoint inhibitor (ICI) therapies. The research revealed that patients
with more inflamed TME have significantly longer overall survival in lung
adenocarcinoma, liver hepatocellular carcinoma, colon adenocarcinoma and head
and neck squamous cell carcinoma. Among other key findings, a high tumor mutation burden (TMB) did not necessarily correlate
with a tumor's inflammatory status, and innate anti-PD1 resistance (IPRES) gene
signature was found to have limited value as a pan-cancer predictive biomarker.
The data-set was derived from the Cancer Genome Atlas
(TCGA) database.
CStone is building an in-house bioinformatics
team at its Translational Medicine Research Center (TMRC) in Suzhou that plans
to carry out further studies using publicly available datasets and CStone's
clinical trial-derived next-generation sequencing data. Dr. Jon Wang, Senior
VP, Scientific Affairs, head of TMRC commented: "Our aim is to be at the
forefront of understanding of predictive biomarkers to better support clinical
trial design, and ultimately to ensure that patients benefit from the right
therapy or combination therapy, and also proper sequence and timing of therapy".
About
CStone Pharmaceuticals Co., Ltd
CStone Pharmaceuticals is a biopharmaceutical company devoted to the development of next-generation innovative drugs. With its broad immuno-oncology pipeline, the firm is pursuing a development strategy focused on combination therapy. In July 2016, CStone announced the completion of its $150 million Series A financing, led by three prestigious VC/PE funds: Oriza Seed Venture Capital, Boyu Capital, and WuXi Healthcare Ventures. All members of the management team are seasoned executives from top multinational pharmaceutical companies. CStone has successfully built up an industry leading team with clinical development and translational medicine as its core competence. With funding and pipeline, CStone is well positioned as the partner of choice for multinational pharmaceutical / biotech companies to develop drugs in China and the Asia-Pacific region.
For more information about CStone
Pharmaceuticals, please visit: http:/
Your privacy is important for us. We use cookies to enhance your experience when visiting our websites: performance cookies show us how you use this website, functional cookies remember your preferences and targeting cookies help us to share content relevant to you. Select “Accept all” for giving your consent to all cookies or select “Reject all” for using only strictly necessary cookies.